DIAGNOMICS INC.

Company Overview

Diagnomics Inc., founded in 2011, markets a range of diagnostics tests and genomic sequencing tools. The main product lines include Diagnomics-on-Cloud products and NGS sequencing reagents.

Diagnomics-on-Cloud tests include NIPD (Down syndrome), NICE (Down syndrome, Edwards syndrome, Patau’s syndrome, trisomy 9, 16 and 22), genetic disease identification (retinal diseases) and BRCARE (hereditary breast and ovarian cancer)

NGS sequencing reagents are marketed under the Accu trade name, and include blood, buccal, circulating, saliva, and urine kits.

Sequencing services include microbiome 16S rRNA sequencing to help consumers understand their unique microbiome. This sequencing service enables better understanding of a person’s nutritional needs and many other wellness indicators, including optimal foods to eat, supplements to take, and how to reach weight goals.

The company offers whole-genome, exome and RNA sequencing. There is an end-to-end NGS service from library prep, sequencing on Illumina HiSeq and MiSeq instruments, and final data analysis.

Company's Business Segments

• Consumer Genomics Solutions : This segment provides distribution, partnering, and reselling opportunities to organizations interested in DNA-based services.
• Analysis Platform : This segment delivers its customers Microassay, NGS, and Qpcr/Open array analysis methods.
• Research Services : This segment provides research and development services and genomics research solutions based on several platforms, including microarrays, advanced sequencing, and real-time PCR.